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The growth hormone receptor (GHR) is a critical regulator of postnatal growth and metabolism. However,
the GHR signaling domains and pathways that regulate these processes in vivo are not defined. We report the
first knock-in mouse models with deletions of specific domains of the receptor that are required for its in vivo
actions. Mice expressing truncations at residue m569 (plus Y539/545-F) and at residue m391 displayed a
progressive impairment of postnatal growth with receptor truncation. Moreover, after 4 months of age, marked
male obesity was observed in both mutant 569 and mutant 391 and was associated with hyperglycemia. Both
mutants activated hepatic JAK2 and ERK2, whereas STAT5 phosphorylation was substantially decreased for
mutant 569 and absent from mutant 391, correlating with loss of IGF-1 expression and reduction in growth.
Microarray analysis of these and GHR/ mice demonstrated that particular signaling domains are respon-
sible for the regulation of different target genes and revealed novel actions of growth hormone. These mice
represent the first step in delineating the domains of the GHR regulating body growth and composition and
the transcripts associated with these domains.
Over the last decade, extensive in vitro studies have identi-
fied signaling pathways triggered by growth hormone receptor
(GHR) activation and the sequence motifs within the con-
served cytoplasmic domain of the receptor that are required to
initiate these pathways. These studies have established the
critical signaling role of JAK2 tyrosine kinase, which is re-
cruited to the trimeric GHR2:GH complex at the box 1/2 motif
(9). Hormone binding initiates JAK2 transphosphorylation
and activation, resulting in phosphorylation of critical tyrosines
within the cytoplasmic domain of the GHR, as well as other
direct JAK2 substrates such as IRS-1 and -2. The distal cyto-
plasmic phosphotyrosines of GHR have been shown to recruit
signal transducer and activator of transcription 5 (STAT5) and
other proteins through SH2-domain interactions, whereas the
proximal JAK2 activation domain is responsible for ERK1/2
and phosphatidylinositol 3-kinase (PI 3-kinase) activation (30),
although it has been claimed that residues distal to m390 are
required for ERK1/2 activation (residue 390, mouse sequence
numbers given throughout) (38). There is some dispute regard-
ing the distal tyrosine residues used to recruit STAT5 for
activation, notably in relation to tyrosine m498 (8, 33); more-
over, it has been claimed that tyrosines m341 and m346, prox-
imal to boxes 1 and 2, may also generate active STAT5 (31).
In vitro studies have identified other signaling elements
within the distal region of the GHR cytoplasmic domain, for
example, a JAK2-independent calcium signaling element be-
tween residues m465 and m517 (30). SHP2 phosphatase can
have a dual role when bound to the cytoplasmic domain of the
GHR. It binds primarily to m606 to attenuate JAK2-STAT5
signaling but can also serve as an adaptor protein (30). GH-
driven activation of STAT5 can also be attenuated by suppres-
sor of cytokine signaling proteins (SOCS proteins). Tyrosine
m498 and other proximal tyrosines are reported to bind
SOCS-3, whereas residues m569 to m650 bind to other SOCS
proteins, SOCS-2, and CIS (25). These SOCS proteins are
believed to inhibit GH-induced gene transcription by compet-
ing with STAT5.
The relevance of these extensive in vitro studies to the in
vivo state has not been established. Until the very recent pub-
lication by Milward et al. (19), there have been no publications
of inactivating clinical mutations within the conserved 352 res-
idue cytoplasmic domain of the GHR, other than an intron 9
donor splice mutation that effectively removes the cytoplasmic
domain (1). STAT5b-deficient (STAT5b/) mice show a re-
duction in circulating IGF-1 (the central mediator of the
growth actions of GH), and STAT5 response elements have
recently been identified within the IGF-1 promoter (5, 35, 37,
41). One would predict that removal of tyrosines critical for
docking of STAT5 would drastically reduce Igf1 transcript and
consequently IGF-1 in serum, leading to reduction in postnatal
growth. However, although STAT5/ mouse models do dis-
play growth retardation, this retardation is not as extensive as
that seen in GHR gene-disrupted (GHR/) mice (4), indi-
cating that other signaling pathways must play a significant
physiological role in potentiating the growth signaling response
of GHR. Moreover, the basis for regulation of the many other
physiological roles of GH, such as the regulation of fat and
carbohydrate metabolism, reproduction, bone turnover, and
extended life span, need to be delineated in vivo by receptor
mutation analysis. This is particularly relevant given that the
sexual dimorphism in secretory pattern of GH is known to be
* Corresponding author. Mailing address: Institute for Molecular
Bioscience, University of Queensland, St. Lucia, Brisbane, Queensland
4072, Australia. Phone: (61) 7-33462037. Fax: (61) 7-33462101. E-mail:
m.waters@uq.edu.au.
† J.E.R. and A.M.L. contributed equally to this study.
66
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
responsible for the sexual dimorphism of many processes in
rodents, particularly hepatic metabolism (34).
Here we report the creation and characterization of the first
knockin mouse models designed to determine how and which
specific regions of the GHR cytoplasmic domain are required
for GH actions observed in vivo. Our phenotypic and microar-
ray analyses with these mutant mice demonstrate that residues
distal to m391 are critical for postnatal growth, STAT5 phos-
phorylation, and IGF-1 activation. However, in the liver the
majority of regulated transcripts, including those for several
novel GH actions, are associated with the proximal JAK2 ac-
tivation domain.
MATERIALS AND METHODS
Gene replacement strategy. The GHR cytoplasmic domain was modified by
homologous recombination with the GHR locus encompassing exons 9 and 10.
Two targeting constructs were designed and generated incorporating a short
homology arm of 1.4 kb upstream of exon 9 and a long homology arm of 4 kb,
including exon 10 and the downstream intronic sequence.
Construction of targeting vector. Probes for the exon 9 and 10 portions of the
GHR were generated by synthetic oligonucleotide creation (Genset Oligos,
Lismore, Australia) or by PCR, respectively (10F, 5-CCTGGGTCGAGTT
CATTGAGC-3, 10R10, 5-GCCCACTTACACCACCCAGC-3, 1-kb exon
10 product).
A 16-kb Sau3A1 fragment containing exons 9 and 10 of the mGHR gene was
isolated from a 129/SVJ mouse genomic  phage library (Stratagene, La Jolla,
Calif.). A 6.4-kb portion of this that contained exons 9 and 10 with a flanking
intronic sequence was cloned into pBluescript by XbaI to use for targeting to
embryonic stem (ES) cells (GenBank accession number AY271378). This frag-
ment was subjected to QuikChange mutagenesis (Stratagene) to introduce rel-
evant mutations to exon 10. Clone 1 was created by two rounds of mutagenesis
to truncate the mature GHR at residue 569 (forward, 5-GCA
TGGAAGCCACGTCTTGTATAAAATAGAGCTTTAACCAAGAGG-3;
reverse, 5-CCTCTTGGTTAAAGCTCTATTTTATACAAGACGTGGCTT
CCATGC-3) and convert Y539/545-F (forward, 5-CTGCCAAGAAAATT
TCAGCATGAACAGCGCCTTCTTTTGTGAGTC-3; reverse, 5-GACTCA
CAAAAGAAGGCGCTGTTCATGCTGAAATTTTCTTGGCAG-3). Clone
2 was treated to one round of mutagenesis to result in truncation of the mature
GHR at residue 391 (forward, 5-GCTGGTATCCTTGGAGCCTAGGATGAT
GATTCTGGGCG-3; reverse, 5-CGCCCAGAATCATCATCCTAGGCTCCA
AGGATACCAGC-3). Both mutants were confirmed by automated sequence
analysis (AGRF, University of Queensland, St. Lucia, Queensland, Australia). A
floxed selection cassette (PGKneoNTRtkpA) (42) was then inserted between
exons 9 and 10 by BamHI and XbaI engineered restriction sites (Fig. 1A).
Production of gene targeted mice. Targeting vector plasmids were linearized
by NotI digest (cutting immediately upstream of the 5 flanking short arm) and
purified by Geneclean II (Qbiogene, Carlsbad, Calif.) prior to electroporation.
FIG. 1. Creation of GHR targeted knockin lines. (A) Targeting strategy for both mutant types with altered exon 10 using neomycin resistance
for selection in ES cells. A Cre/lox system was adapted to remove the selection cassette. (B) Southern confirmation of heterozygous ES cell clones
for mutant 569 (1), mutant 391 (2), and mutant 391 transiently transfected with Cre recombinase (3). (C) Northern blot analysis confirmed that
Ghr and Ghrbp (GH-binding protein) mRNA was expressed in hepatic tissue in both mutants 569 and 391 in both heterozygous (H) and
homozygous forms. (D) Western blotting of hepatic microsomal membranes with cytoplasmic domain specific antibody detected truncated mutant
569 GHR protein; however, the epitope was absent from mutant 391.
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The vector was electroporated into low-passage 129/SVJ agouti ES cells, and
homologous recombinants were selected for by G418 resistance, followed by
genotyping. Positive heterozygote recombinants were Cre deleted by transient
transfection with pMC-Cre (7) to remove the PGKneoNTRtkpA selection cas-
sette from the genome. ES cells minus the selection cassette but retaining the
desired GHR mutations (569 and 391) were confirmed by Southern blotting
(described below). Cre-deleted ES cells were then injected into C57 black blas-
tocysts and implanted in pseudopregnant foster mothers housed in a specific-
pathogen-free facility. Chimeric offspring were mated with C57 black mice to
produce germ line heterozygote offspring. Some chimeras were generated by
injection of heterozygote ES cells that had not been Cre deleted. In this case, Cre
deletor transgenic mice were obtained (29), which ubiquitously express Cre
recombinase enzyme. These were mated with the F1 germ line mice and the
chimeric males, which still carried the selection cassette.
Genotyping strategies. Southern blotting was used for genotyping as described
previously (28). HindIII-digested genomic DNA was electrophoresed, trans-
ferred to a nylon membrane (Hybond N; Amersham Pharmacia, Sydney, Aus-
tralia), and hybridized to a probe corresponding to a 1.4-kb HincII/XbaI frag-
ment of upstream external intron 8/9 of the murine GHR. The probe was labeled
with [-32P]dCTP by random priming with a commercially available kit (Mega-
prime DNA Labeling Systems; Amersham Pharmacia). The 7-kb fragment cor-
responded to the wild-type (WT) locus, whereas a 6-kb fragment was observed
for the targeted locus (Fig. 1B, left panel). Analysis of Cre recombination was
performed identically with the exception of EcoRI restriction digest, followed by
hybridization to a probe corresponding to exon 10 as described earlier. In this
case the WT locus yielded a 4.3-kb band, the targeted locus yielded a 5.3-kb band,
and the Cre-deleted targeted locus yielded a 1-kb band (Fig. 1B, right panel).
Animals. Animals were housed in an approved facility and treated in accor-
dance with university guidelines, and all procedures were approved by the Uni-
versity of Queensland Animal Ethics Committee and the Australian Office of the
Gene Technology Regulator. Water and feed pellets were available ad libitum
under a 12-h light-dark cycle at 20 to 22°C. Fasting of the animals was performed
overnight (16 h) with animals having water ab libitum. All animals passed stan-
dard virus screens quarterly throughout.
IGF-1 measurements. Acid ethanol-extracted serum IGF-1 was measured by
using an IGF-1 radioimmunoassay kit (Bioclone, Sydney, Australia) according to
the manufacturer’s instructions.
RNA extraction and Northern blot analysis. Liver RNA samples from 42-day-
old mice were isolated by using RNA-Bee reagent (Tel-Test, Inc., Frienswood,
Tex.). Samples were separated on a denaturing gel (28) in morpholinepropane-
sulfonic acid buffer and transferred onto an MSI membrane (Micron Separa-
tions, Westborough, Mass.). Hybridizations were performed by using Northern
Max (Ambion, Austin, Tex.) and [-32P]dCTP-labeled (Megaprime Labeling
Systems; Amersham Pharmacia) cDNA probes. The rat IGF-1 cDNA was kindly
provided by Adrian Herington (QUT, Brisbane, Australia). The mouse GHR
cDNA was kindly provided by Frank Talamantes (University of California, Santa
Cruz, Calif.), and a probe encompassing exons 2 to 7 was prepared from this
cDNA by restriction digest with HindIII and EcoRV. Probes for Sth2, Es31, Ang,
Socs2, and Csad were generated by reverse transcription-PCR with primers am-
plifying the same sequence as that targeted by Affymetrix oligonucleotide probe
sets.
The loading control hybridization was performed with an 18S specific oligomer
5-CATGGTAGGCACGGCGACTACCATC-3 (Genset Pacific, Pty., Ltd.) or a
150-bp fragment of 28S cDNA.
Microarray analysis. Liver samples from mice were dissected directly into
RNAlater solution (Ambion), and total RNA was extracted by using an
RNAqueous kit (Ambion) according to the manufacturer’s instructions; the
quality of the RNA was confirmed by spectrophotometry and gel electrophoresis
(a compilation of samples, their codes, and their accession numbers is available
at http://research.imb.uq.edu.au/mwaters/ghr/). Samples from GHR/ mice
were further purified by using LiCl precipitation before cDNA synthesis. A total
of 5 g of the total RNA was used in the double-spaced cDNA synthesis by use
of a MessageAmp kit (Ambion); the procedure was performed according to the
manufacturer’s instructions. The in vitro transcription reaction was performed by
using an Enzo kit (Affymetrix, Santa Clara, Calif.) according to the manufactur-
er’s instructions (except for increasing the reaction time to 14 h), and 15 g of
cRNA was used to hybridize to an Affymetrix U74v2A array for 16 h. The arrays
were subsequently washed and stained on the fluidic station and scanned on a
confocal scanner (Affymetrix). The results were analyzed by using MAS 5.0 and
the Data Mining Tool (DMT; Affymetrix). Each sample was processed by using
Affymetrix MAS 5.0 software to visually check the array image and grid align-
ment and to compute signal values for each probe. Preliminary data analysis was
applied to normalize the results by using global scaling to a set value of 100.
Furthermore, quality control analysis by using the spikes, percent present, inter-
nal control of 3/5 ratios for -actin and Gapdh, noise, and background was
performed before further analysis was undertaken. The increases and decreases,
as well as the signal log ratios (SLRs; equivalent to fold changes) were identified
with MAS 5.0, and then the comparisons were loaded into DMT (Affymetrix),
which allowed identification of transcripts changing in the same direction and the
number of comparisons in which they change. In our case three separate mice
were analyzed for each experimental group, allowing nine separate comparisons
with another group (http://research.imb.uq.edu.au/mwaters/ghr/). DecisionSite
7.2 for Functional Genomics and DecisionSite Statistics software (Spotfire, Som-
erville, Mass.) was used for clustering and statistical analyses on the samples.
Genes that were called absent were eliminated from the initial comparisons.
These were later reanalyzed, and the transcripts changing from absent in one
group to present in the other were scored as increases, while the ones changing
from present to absent were scored as decreases. Finally, a gene was scored as
significantly changed in one group in comparison to the other if it was changed
in the same direction in at least eight of nine comparisons performed and the
fold change was 	1.5.
Gene ontology (GO) classification was used to assign transcripts into func-
tional groups by using the GO browser through the NetAffx at Affymetrix; to
generate Table 3 we used only single GO terms (a full classification of the
transcripts is available at http://research.imb.uq.edu.au/mwaters/ghr/). All of
the gene names reported in the present study are MGI approved and details
about them can be found through the MGI website (http://www.informatics.jax-
.org/) or through the NCBI website (http://www.ncbi.nlm.nih.gov).
Accession numbers for microarray data. The microarray data presented here
has been submitted to a public database, and the accession numbers have been
obtained from GEO (http://www.ncbi.nlm.nih.gov/geo): GSM15488, GSM15489,
GSM15490, GSM15491, GSM15492, GSM15493, GSM15494, GSM15495,
GSM15496, GSM15497, GSM15498, and GSM15499 (http://research.imb.uq
.edu.au/mwaters/ghr/).
Western ligand blotting. Recombinant rat IGF-1 (Gropep, Adelaide, South
Australia, Australia) was iodinated by the iodogen method and purified by using
Sephadex G-50 chromatography. Western ligand blotting was performed as de-
scribed previously (12), and blots were analyzed by densitometry. Relative 125I-
IGF-1 bound to IGFBPs was calculated from the integrated optical density value
per sample. Bands at 38.5 to 41.5, 32 to 34, and 30 kDa correspond to IGF-
binding protein 3 (IGFBP-3); IGFBP-1, -2, and -5; and IGFBP-4, respectively
(12).
Immunoprecipitation and immunoblot analysis. Immunoblot analysis for
JAK2, STAT5, and ERK1/2 phosphorylation was carried out on hepatic homog-
enates obtained from 19-day-old mice injected intraperitoneally with 4 g of
bovine GH (bGH; Monsanto Company, St. Louis, Mo.)/g (body weight) and
sacrificed 15 min later. Liver homogenates were used in immunoprecipitation
with JAK2 (sc-278) and STAT5 (sc-835) antibodies from Santa Cruz Biotech
(Santa Cruz, Calif.), and samples were separated on a polyacrylamide gel, blotted
onto a nitrocellulose membrane, and probed with antiphosphotyrosine 4G10
antibody. ERK1/2 immunoblots were performed according to the information
sheet accompanying the Phospho-p44/42 mitogen-activated protein kinase
(Thr202/Tyr204) antibody from Cell Signaling Technology (catalog no. 9101)
(Beverly, Mass.). The only exception to the protocol was that 2% (wt/vol) bovine
serum albumin (fraction V; ICN, Aurora, Ohio) was used instead of 5% nonfat
skim milk powder for incubation with the antibodies. Immunoblots were also
carried out for HNF1, -3, and -6 (sc-6554 and sc-6559; Santa Cruz Biotech) with
samples of adult liver by using immunoprecipitation and blotting with a second
species of antibody, with normalization by protein loading, and by reprobing for
the primary antibody. Loading control was performed by using immunoprecipi-
tation antibody (JAK2 and STAT5) or ERK1 (sc-93; Santa Cruz Biotech).
Proteins were detected by using ECL Plus Western blotting reagent (Amersham)
according to the manufacturer’s instructions. Bands on film were quantified with
a Bio-Rad imaging densitometer GS-700 and software.
GHR measurements. Immunoblot analysis for GHR in liver membranes from
42-day-old mice was carried out according to the method of Lobie et al. (15) with
a polyclonal antibody raised against a glutathione S-transferase fusion of the
rabbit GHR cytoplasmic domain. Ligand binding with 125I-bovine GH was car-
ried out according to the method of Waters and Friesen (40).
RESULTS
Targeted mutation of the GHR. To elucidate the role of the
GHR cytoplasmic domain sequence motifs and their target
signaling cascades in manifesting the in vivo actions of GH,
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knockin mice bearing cytoplasmic domain mutations through
targeted homologous recombination in ES cells were created
(Fig. 1A). The resulting mice express murine GHR proteins
either truncated at proline m569, together with conversion of
tyrosines m539 and m545 to phenylalanine (mutant 569), or
truncated at lysine m391 (mutant 391) (Fig. 2A). The Y539/
545F mutations were introduced to allow us to determine
whether, in vivo, all STAT5 signaling originates distal to tyro-
sine m539 (as proposed by Hansen et al. [8]), or whether
tyrosine m498 and potentially more proximal residues are re-
quired, as first proposed by Smit et al. (31). Homozygous
mutant 569 or mutant 391 mice were generated by mating
heterozygous mice carrying one copy of the 569 or 391 muta-
tion, respectively. Correct homologous recombination was con-
firmed by restriction digest and Southern blotting, and expres-
sion of the mutant GHRs was demonstrated by Northern and
Western blotting of hepatic tissue, together with sequencing of
the mRNA transcript (Fig. 1B to D). The unavailability of an
antibody recognizing the extracellular domain of the murine
receptor in Western blots precluded determination of the mo-
lecular size of protein produced by the 391 truncation mutant.
However, radioreceptor assays confirmed normal levels of spe-
cific binding of 125I-labeled bGH, i.e., 3.3% 
 1.1% WT and
2.8% 
 0.8% mutant 391 (mean 
 the standard error of the
mean [SEM]), expressed per milligram of membrane protein
(n  3 samples), to the receptor in this mutant.
Signaling by mutant GHR. The main aim of the present
study was to determine the effects of mutations changing the
intracellular signaling of GHR on growth and metabolism.
Therefore, the relative phosphorylation of main effectors of
GH stimulation, such as JAK2, ERK1/2, and STAT5, was
compared 15 min after mice were injected with bGH or saline.
In order to observe a direct response to GH, 19-day-old mice,
which have low endogenous GH secretion (2) were used. Both
mutants displayed a JAK2 phosphorylation response (Fig. 2B
and E) and ERK1/2 activation (Fig. 2C and F) by GH that was
not significantly different from that of WT mice with similar
fold induction. In contrast, mutant 569 mice exhibited a sub-
FIG. 2. Signaling in mutant mice in response to GH injections. (A) Predicted binding of signaling and adaptor molecules to the cytoplasmic
domain of the GHR of the WT, mutant 569, and mutant 391. (B to D) Livers from the bGH- and saline-injected 19-day-old mice were used in
immunoprecipitation analyses 15 min after the injections. Loading for each of the proteins was confirmed by using antibodies specific for an
appropriate protein. (B) Antiphosphotyrosine (PY) immunoblot of JAK2 immunoprecipitated from liver homogenate. (C) Immunoblot for active
ERK1/2 (Phospho-p44/42 mitogen-activated protein kinase) from liver homogenate. (D) Antiphosphotyrosine (PY) immunoblot of STAT5
immunoprecipitated from liver homogenate. (E to G) Densitometric quantification of the blots from panels B to D. Signals for the activated JAK2
(E), ERK1/2 (F), and STAT5a/b (G) were normalized for loading. The data for all graphs are presented as means 
 the SEM.
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maximal STAT5 tyrosine phosphorylation response (29
 10%
of WT [mean 
 the SEM; n  6]), whereas no response was
detectable in mutant 391 (Fig. 2D and G).
Postnatal growth rate and organ weights. Homozygous mice
carrying the mutations remained phenotypically normal until
ca. 3 weeks of age, after which a clear deviation in growth rates
became apparent (Fig. 3), being more obvious in the mutant
391 than in mutant 569 (Fig. 3A to C). The 391 mutants grew
significantly more than the GHR/ mice, which were kindly
supplied by J. J. Kopchick and K. T. Coschigano (45). Hetero-
zygotes for both mutant types also showed a significant impair-
ment of postnatal growth and a reduction in hepatic IGF-1
transcripts, suggesting competitive inhibition of the full-length
GHR at the cell surface by mutant receptor subunits, forming
heterodimeric complexes (data not shown). A pronounced het-
erozygote effect has been reported for patients expressing cy-
toplasmic domain truncated mutant GHRs, which are overex-
pressed at the cell surface with long residence times (1).
Organ weights were measured at 60 days for mutants 569
and 391 and compared to WT and GHR/ controls. A pro-
portional reduction in absolute organ weight was observed with
severity of truncation. When the organ weight was normalized
to the body weight (Fig. 3D), the spleen weight was reduced in
mutant 391 (P  0.05), whereas the kidney size was reduced in
mutant 391 and the GHR/ control (P  0.01 for both). A
disproportionate reduction in liver weight was also found for
mutant 391 and the GHR/ control compared to WT con-
trols (P  0.01 for mutant 391 and P  0.05 for GHR/
control). On the other hand, the brain/body weight ratio was
disproportionately increased in mutants 569 and 391 (P  0.01
for both), as has been previously reported for the GHR/
mice. This has been attributed to the fact that brain growth is
virtually complete prior to 3 weeks postnatal age, before
growth hormone influences postnatal growth (16).
The GHR/ male mice showed a significant reduction in
the size of the epididymal adipose pad (P  0.05) in young
adult animals (mice 60 days old) (Fig. 3D), but no reduction
was observed in mutants 391 and 569. However, in older males
(4 and 10 months), an increase in the relative weight of fat pads
in all fat depots has been noted. The difference from WT mice
in the amount of fat was most dramatic in the subcutaneous fat
pad (Fig. 3E) and increased with age. This increased obesity
was associated with substantial fasting hyperglycemia (Fig. 3F)
in older mice. At the same time, no differences in fat depots or
fasted glucose levels were observed in females at up to 8
months of age.
IGF-1 axis. IGF-1 is a major mediator of the growth actions
of GH, so correlations between IGF-1 level and growth rates
were sought. Changes in the IGF-1axis were observed for both
mutant lines (Fig. 4). The levels of hepatic Igf1 transcripts were
reduced for both mutant types (to 36% [Igf1b transcript] and
67% [IGF1a, major transcript] of WT for mutant 569 and to 9
to 11% [both transcripts] of WT for mutant 391). However, the
IGF-1 level in serum was reduced further than would be indi-
cated by hepatic transcript changes (16 to 21% of WT for
mutant 569 and 10% of WT for mutant 391 [Fig. 4B]).
Ligand blotting with radiolabeled IGF-1 revealed no consistent
changes in the levels of IGFBP-1, IGFBP-2, IGFBP-4, and
IGFBP-5 in the sera of 42-day-old mice (Fig. 4C). However, a
moderate reduction in IGFBP-3 levels was observed for mu-
FIG. 3. Postnatal growth reduction of the GHR mutant mice. (A) Photograph of WT and mutant homozygous 60-day-old male mice. (B to D)
Color coded as follows: WT (black), mutant 569 (blue), mutant 391 (red), and GHR/ (green). (B and C) Postnatal growth curves (B, females;
C, males). All mice were weighed over a period of 60 days. The results are presented as mean body weight 
 the SEM (n  8). Growth was
significantly reduced in all mutants compared to WT (P  0.001).(D) Organ weights were recorded at 60 days postnatally. The results are shown
as relative to body weight and are expressed as means 
 the SEM (n  6 to 8). The sizes of some organs were significantly reduced (all changes
are marked with a single asterisk due to space constraints; P  0.01 for all changes, except P  0.05 for spleen in mutant 391 and liver in GHR/
mice). (E) Subcutaneous fat pad sizes at 4 (■) and 10 () months in male mice. The results are expressed relative to body weight and are means

 the SEM (n  3 to 4). ❋❋, P  0.01; ❋, P  0.05. (F) Glucose levels in 10-month-old males after a 16 h fasting (n  3) and are shown as means

 the SEM (❋, P  0.01).
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tant 569 (33 to 52% of WT), whereas a severe reduction of
IGFBP-3 levels was seen with mutant 391 (6.2% of WT) and
GHR/ mice (11.6% of WT). The severity of IGF-1 reduc-
tion in serum (compare Fig. 4A with Fig. 4B) suggests that
additional IGF-1 degradation is taking place due to a lack of
sufficient ternary ALS/IGFBP-3/IGF-1 complex to maintain a
circulating IGF-1. In fact, microarray analysis (described be-
low) showed that hepatic Igfals transcripts were reduced by
1.8-fold in mutant 569 and were absent in mutant 391 and
GHR/ mice (see Table 1).
Because the decrease in hepatic Igf1 transcripts and of IGF-
1 in serum in the 391 mutant line was substantially greater than
that reported in the STAT5a/b double-null mice (35), alter-
ations in other hepatic factors that regulate IGF-1 production
were sought. A major decrease in HNF3 protein in the 391
mutants and a significant decrease in the 569 mutants were
observed, whereas HNF1 remained unchanged (Fig. 5).
Microarray analysis of GHR knockin mice. A second aim of
the present study was to relate particular signaling domains of
the receptor to particular sets of GH-regulated genes. Accord-
ingly, Affymetrix U74Av2 microarrays were used to examine
differences in hepatic transcript expression between the two
lines of mature mutant mice and WT littermates. GHR/
mice, without a functional GHR, were also included to deter-
mine the full extent of GH action in regulating the hepatic
transcriptome (45). The average number of present calls was
35.9% so, on average, 4,483 transcripts were detected in the
samples analyzed. The direction of changes in expression, in
relation to a baseline of WT, was determined by MAS 5.0
software and, to be considered a significant change, was re-
quired to be at least 1.5-fold different and changed in the same
direction in at least eight of nine comparisons when analyzed
by using Affymetrix DMT. Changes in seven of nine compar-
isons were considered likely changes but, unless a confirmation
was performed, these results were not included in the present
study. This fold cutoff was selected because previously it has
been reported to define regulated genes (43). This was con-
firmed in our experiments by analysis of Igf1 transcripts, for
which MAS 5.0 identified a 1.5-fold decrease for mutant 569,
and which was shown to be significant both by Northern blot
analysis and by IGF-1 immunoassay in serum (Fig. 4A and B).
Differential gene expression in mutant 569, mutant 391, and
GHR/ mice compared to the WT. A set of 403 transcripts,
representing 398 individual genes, which were differentially
expressed across all animal groups and which met the above
criteria, were identified. Twenty transcripts were common be-
tween the three receptor mutants in comparison to WT mice,
with 13 unique to mutant 569, 59 unique to mutant 391, and
268 unique to the GHR/ line (Fig. 4A and Table 1). Further
analysis was performed with a subset of the 398 genes that
passed stringent MAS 5.0 criteria (change P 0.0025 and SLR
	 1 or SLR  1) by using an analysis of variance t test with a
cutoff score of P  0.0005. Such a combination of criteria
guarantees the lowest possible number of false positives (18,
24). Using these criteria, we have identified five genes to be
regulated exclusively by m569-650 (Y539/545-F). The fold
changes for these genes did not vary significantly between the
mutant 569, 391, and GHR/ lines and P 	 0.0005. There
were four genes upregulated to a similar extent in all groups
(Gstt1, Ang, Papps2, and Serpina6) and only one gene similarly
downregulated (Fabp5) with at least one of the genes, Serpina6
(corticosteroid binding globulin) known to be a direct GH
target. This implies that most of the active STAT5, as well as
SHP2, which binds in the m569-650 sequence, plays only a
minor role in GH signaling to the genome. This upregulation
of four of five genes and the fact that the majority of transcripts
FIG. 4. IGF-1 axis in GHR mutant mice. (A) Densitometric quantification of a Northern blot analysis of the IGF-1 levels in GHR mutant mice
and WT littermates. Transcripts of 0.9 to 1.2 kb were used for this analysis. The data are shown as percentages of WT and are displayed as means

 the SEM (n  10). (B) Levels of IGF-1 serum as measured by radioimmunoassay (see Materials and Methods) were significantly decreased in
mutant 569, mutant 391, and GHR/ mice in comparison to WT (P  0.001). The results are shown are means 
 the SEM (n  7 to 11).
(C) Western ligand blot profile of IGFBP levels in serum in mice at 42 days shows a significant decrease in the levels of IGFBP3 (P  0.001), with
no change detected in the remaining IGFBPs.
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changed in mutant 569 (Fig. 6A) were upregulated reinforces
the fact that the most distal part of the receptor is important
for negative modulation of GH-induced gene expression. Fur-
thermore, the set of 20 common genes (Table 1), which were
regulated concordantly in the mutant 569, mutant 391, and
GHR/ mice, was identified. These genes can be reasonably
assigned as STAT5-regulated genes since they included known
STAT5-regulated genes such as Igf1, Igfals, Socs2, P450 cyto-
chrome, Cyp2b9, and some metabolic enzymes. Eleven of these
were upregulated (e.g., Sth2, Hao3, and Ang), and nine were
downregulated (e.g., Igfals, Igf1, EgfR, and Comt); among these
genes at least seven are currently known to be direct targets of
GH-induced signaling. Increased downregulation of the Igf1
transcript in the 391 mutant suggests that the residual 30% of
active STAT5 plays an important role in regulation of Igf1 (and
presumably many other) transcripts, and Igf1 mRNA levels are
critically dependent on STAT5 both in vitro and clinically,
based on loss-of-function studies (13, 41).
The analysis of the 121 transcripts altered in the mutant 391
showed that the majority of transcripts were not affected in
mutant 569 and that 41 of them were not different from the
GHR/ mice (e.g., Apcs, Es31, Cdkn1c, Ndufb8, Iigp-pending,
LifR, and Mug-ps1) (Table 2 and Fig. 6A). The expression of
these genes, as well as genes regulated preferentially in mutant
391 mice (Hsd3b3 and Hsd3b6), may be directed by the signal-
ing proteins docking at all or some of the three tyrosines that
were removed by the 391 mutation (residues m402, m465, and
m498), which would include residual STAT5. The promoters
of these genes may be either particularly sensitive to STAT5 or
dependent on other signaling pathways within the m391-569
sequence. Such pathways include the Ca2 signaling element
between m465 and m517 and potentially other uncharacterized
pathways.
The largest number of altered transcripts was observed for
GHR/ mice (n  330), providing a striking contrast to the
121 regulated transcripts for mutant 391 mice despite a very
similar extent of growth retardation. These genes, presumably
directly regulated by JAK2 and associated ERK1/2 and PI
3-kinase pathways, as well as negatively by SOCS proteins,
include many metabolic genes, as well as genes regulating
signaling, proliferation, translation, and transporter proteins.
Such genes represent the core functions of the hepatocyte and
are most likely regulated by elements common to all cytokine
and tyrosine kinase receptors. Some of these genes have been
shown to be directly regulated by GH (e.g., Igf1, Socs2, or
Comt) (36) (Tables 1 and 2); some are likely to be regulated by
transcription factors induced by GH signaling. In fact, the
important differences between the GHR/ mice and the mu-
FIG. 5. Regulation of hepatic nuclear factors in GHR mutant mice. (A and B) Western blot analysis of the expression of HNF3 (A) and
HNF1 (B) in the livers of 10-month-old mice fasted for 16 h. Both HNFs were immunoprecipitated from the liver homogenates, and
immunoglobulin G light chain was used as a loading control. (C and D) Densitometric quantification of the results from panels A and B are shown
as means 
 the SEM (n  3). , P  0.001.
TABLE 1. Genes regulated concordantly in mutant 569,
mutant 391, and GHR/ mice
Gene
Fold changea Known
regulation
by GHb
Mutant
569/WT
Mutant
391/WT
GHR//
WT
Genes upregulated in
all three groups
Ang 2.1 3.3 2.8
Cyp2b9 5.2 10.9 15.3
Cyp4a10 2.1 2.6 2.0
Cyp17a1 3.4 4.0 2.5
Gsta4 2.2 2.5 4.7
Gstt1 1.6 2.2 1.6
Hao3 3.8 11.7 9.4 
Papps2 1.6 3.0 2.3
Serpina6 2.0 2.6 3.1 
Sth2 	10* 	10* 	10* 
Sultn 1.8 2.4 1.9
Genes downregulated in
all three groups
1100001G20 3.0 10† 10†
Comt 1.9 4.2 2.8 
Csad 2.6 6.2 6.1
Egfr 101841_at 2.5 10† 10† 
Egfr 101842_g_at 10† 10† 10† 
Fabp5 3.3 4.1 4.6
Hsd3b5 24.7 10† 10†
Igfals 1.8 10† 10† 
Orm1 1.8 5.5 2.7 
a Values indicate changes with WT values as a baseline. *, transcript absent in
WT mice; †, transcript absent in mutant mice as determined by MAS 5.0 soft-
ware.
b , regulation detected.
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tant mice were the upregulation of transcription and elonga-
tion factors (e.g., Nr4a1, Bcl6, Egr-1, Dbp, and Tcea3) and the
upregulation of translational factors (e.g., Sui1-rs1, Eef1d, and
Ict1), none of which was significantly changed in mutants 569
and 391. This suggests that in GHR/ mice a number of
transcripts regulated by these factors would be expressed at a
higher level than in WT mice. This could account for a sub-
stantial proportion of the genes uniquely increased in the
GHR/ mice compared to the mutants and WT (e.g., Rgs16,
Cops3, Ppap2a, Gphn, and Gkap42-pending).
Classification of the regulated genes by GO highlights the
main differences and similarities between the four lines of
mice (Table 3 and http://research.imb.uq.edu.au/mwaters
/ghr/). We have explored the relationships between cell lines by
using hierarchical clustering based on all transcripts (Fig. 6B)
or based on metabolic genes (Fig. 6C). Mutant 569 and WT
were most similar in both analyses, and although mutant 391
was similar to mutant 569 and WT based on overall gene
expression, mutant 391 appeared to be more similar to
GHR/ mice in relation to metabolic genes. Both of these
observations support our phenotypic findings (Fig. 2 and 3), in
that mutant 391 retains JAK2 and ERK1/2 signaling and thus
FIG. 6. Global analysis of the GHR mutant mice by using microarrays. (A) Venn diagram showing the number of genes differentially expressed
in the three knockin lines compared to WT mice and the number of genes up- and downregulated in each group. Genes expressed in common
between the mutants are indicated by overlaps of the circles. (B and C) Hierarchical clustering was performed with DecisionSite 7.2 software
(functional genomics module). (B) Mutant 569 is most similar in its pattern of gene expression to the WT, and mutant 391 is similar to these two
groups and to GHR/ mice cluster separately. This clustering was generated by using the average signal (n 3) for all probe sets from the arrays,
with exclusion of genes absent in all groups. (C) Metabolically, mutant 569 is most similar to WT mice in its gene expression pattern, whereas
mutant 391 is most similar to GHR/ mice. This clustering was performed by using average signal (n  3) for probe sets representing genes
encoding proteins involved in metabolism. (D) Northern blot confirmation of microarray results. Total RNA from the 42-day-old mice was run on
a 1% denaturing gel, blotted onto a nylon membrane, and probed with probes targeting the same region of the gene as the Affymetrix probes. The
blot was then reprobed with 18S oligomer probe to confirm loading. (E) Changes in signaling and GH-dependent growth in GHR/ mice. A
summary of the results shows that in WT mice 100% signaling through all major pathways contributes to 100% of GH-dependent growth, whereas
in mutant 569 the loss of 70% of STAT5 signaling results in the loss of 66% of GH-dependent growth, and the absence of active STAT5 pathway
in mutant 391 is not adequate to reduce GH-dependent growth to zero; these mice retain 11% of this growth. Metabolic pathways identified by
GO analysis and examples of genes belonging to each category that were differentially expressed are shown (http://research.imb.uq.edu.au
/mwaters/ghr/).
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should be more similar to mutant 569 and WT than to
GHR/ mice. On the other hand, the levels of STAT5-de-
pendent transcripts such as Igf-1 and Socs-2 in mutant 391 were
more similar to GHR/ mice (Table 2 and Fig. 6D). Mutant
391 and GHR/ also shared similar alterations in transcripts
encoding a number of transporters, signaling molecules, and
cytochromes, as well as electron transport proteins. This GO
analysis supports the view that we have delineated functional
domains within the cytoplasmic signaling unit of the GHR in
vivo.
DISCUSSION
A main aim of this study was to define the region(s) of the
GHR cytoplasmic domain responsible for enhancing postnatal
TABLE 2. Genes that are specific to the signaling domains of the ICD of the GHR
Gene Changea
Known GH-
regulated
genesbAFFY IDd Name
GHR/ Mutant 391 Mutant 569
Fold Type Fold Type Fold Type
Genes not changed in mutant 569
95620_at 2310016E22Rik 2.3 I 2.0 I 1.4 NC
95471_at Cdkn1c 2.1 I 2.6 I 1.1 NC
93581_at Ndufb8 2.7 I 2.4 I 1.3 NC
104072_at Apcs 2.7 D 2.8 D 1.3 NC
99941_at Es31 10* D 10* D 1.4 NC
103963_f_at ligp-pending 3.8 D 3.0 D 1.1 NC
96938_at Keg1 10* D 10* D 1.5 NC
97680_at Mug-ps1 2.3 D 2.5 D 1.2 NC
101910_f_at Mup1 4.2 D 3.8 D 1.3 NC 
161815_f_at Mup1 5.0 D 5.9 D 1.3 NC 
102096_f_at Mup1 5.9 D 6.5 D 1.4 NC 
101566_f_at Mup1 3.9 D 2.6 D 1.1 NC 
101909_f_at Mup3 4.0 D 3.7 D 1.3 NC
101682_f_at Mup4 4.3 D 4.3 D 1.3 NC
101635_f_at Mup5 4.0 D 3.5 D 1.3 NC
Genes changed in mutant 569 and not
different between mutant 391 and
GHR/ mice
95546_g_at Igf-1 10* D 10* D 1.5 Dc 
99475_at Socs2 10* D 10* D 1.2 Dc 
Genes not changed in mutant 569 and
mutant 391
93986_at 2410003A14Rik 2.1 I 1.1 NC 1.2 NC
94844_at 2810465O16Rik 2.8 D 1.1 NC 1.2 NC
97201_s_at 2900002J19Rik 2.0 I 1.3 NC 0.0 NC
102804_at Ceacam1 2.3 D 1.3 NC 1.1 NC
160711_at Decr1 2.4 I 1.6 NC 1.2 NC 
92571_at Hspa4 2.0 I 1.1 NC 1.1 NC 
162006_r_at Immt 4.2 D 1.3 NC 1.1 NC
94056_at Scd1 2.4 D 1.3 NC 0.0 NC 
93348_at Timm22 2.0 I 1.3 NC 1.3 NC
Genes gradually changing in mutant
569, mutant 391, and GHR/
mice
99669_at Lgals1 3.2 I 1.9 NC 1.1 NC
161161_r_at Nme1 5.3 D 1.9 NC 1.2 NC
100437_g_at Orm1 2.7 D 5.5 D 1.7 D 
95030_at Prlr 4.9 D 2.3 D 1.7 Dc 
99591_i_at Rdh11 3.3 D 2.0 D 1.6 NC
103465_f_at Saa2 3.6 I 1.6 NC 1.3 NC
93084_at Slc25a4 3.1 I 1.4 NC 1.1 NC
161257_r_at Snx17 4.4 D 2.6 Dc 1.7 NC
Genes changed in mutant 391 only
98401_at Hsd3b3 1.1 NC 3.1 D 1.1 NC
102729_f_at Hsd3b6 1.3 NC 3.0 D 1.2 NC
a Values are changes with WT values as a baseline. Change types were identified by MAS 5.0 software in comparison to the WT base file: NC, no change; I, increase;
D, decrease. *, transcript absent in mutant mice as determined by MAS 5.0 software.
b , regulation detected.
c Decrease or increase in seven of nine comparisons (indicating a likely change).
d AFFY ID, Affymetrix identification number.
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growth, since no cases of GH insensitivity had been reported
for the signaling domain other than those involving the JAK2
binding box 1 sequence. The approach used here allows us to
conclude that the distal 80 residues and the tyrosines previ-
ously thought to be responsible for all or most of the STAT5
generation account for 70% of STAT5 generation and 44% of
the GH-responsive postnatal growth in the male (30) (Fig. 6E).
The remaining 30% of STAT5 signaling appears adequate to
retain relatively normal gene expression, even of genes known
to be STAT5 responsive. This includes the main Igf1 transcript,
which was decreased by 33%. The overall correlation be-
tween STAT5 activation and Igf1 transcript level is concordant
with recent studies implicating STAT5 in the generation of
IGF-1 (41). Surprisingly, the modest decrease in Igf1 tran-
scripts in the 569 line was associated with a substantial drop in
IGF-1 in serum of ca. 80%, which appears to be necessary to
achieve major growth retardation. It is likely that the level of
free IGF-1 is higher in the 569 line owing to a decreased
expression of IGFBP3 and IGF-ALS, which are strongly reg-
ulated by the terminal 80 residues. Because the STAT5a/b-null
mice do not display the severity of growth phenotype and
IGF-1 loss seen with the 391 line (which lacks the ability to
generate STAT5a/b), we looked for other hepatic transcription
factors that regulate IGF-1 and which are associated with the
391-to-569 sequence. Both HNF1 and HNF3 have been
implicated in transactivation of the IGF-1 gene promoter (20,
21). Although HNF1 expression was not altered in the 391 or
569 mutant lines, HNF3 expression was markedly decreased
in the 391 line but was also significantly reduced in the 569 line
(Fig. 5). This provides an indication, for the first time, that GH
may regulate hepatic IGF-1 production by a combination of
STAT5a/b and HNF3, generated from the distal part of the
GH receptor signaling domain. However, the interrelations of
the hepatic nuclear factors are complex (26), and HNF3 is
induced by HNF6, which is itself under GH control via
STAT5b and HNF4, the latter being rapidly and directly acti-
vated by GH in a manner which is thought to involve direct
tyrosine phosphorylation (14), either of HNF4 or of its inhib-
itory regulator FKHR (10). Loss of STAT5 activation could
explain the significant reduction of HNF3 seen in the 569
mice, with the severe decrease in the 391 being a result of loss
of both STAT5b and receptor-dependent HNF4 activation.
This severe loss is unlikely to involve the other major regulator
of HNF3 expression, C/EBP (27), since this is activated by
the ERK pathway (23), which is not affected in the 391 mutant
line.
It is significant that the loss of all STAT5 signaling (391 line)
is associated with a growth retardation almost as severe as
receptor deletion, whereas ERK1/2 signaling is not affected. It
can be concluded that non-STAT5/JAK2 signaling, including
ERK and STAT3 signaling, can alone account for only ca. 10%
of GH-responsive postnatal growth. This contrasts with a sim-
ilar targeted knockin study with the EPO receptor, where re-
moval of all cytoplasmic tyrosine residues resulted in only a
minor effect on erythropoiesis (44). The residual 10% of GH-
responsive postnatal growth even in the absence of detectable
STAT5 activation and IGF-1 in serum in mutant 391 may
represent the IGF-1-independent, GH-dependent element in
postnatal growth (14%) identified by Lupu et al. (16) based on
IGF-1/ and GHR/ crosses. In that study, IGF-1 receptor-
dependent postnatal growth amounted to 70% of total post-
natal growth, with 17% of postnatal growth being independent
of either GH or IGF-1 (16). This GH-dependent, but IGF-1-
independent growth may correspond to that seen in myeloid
cells stably expressing 351 truncated GHR, which proliferate
normally in response to GH (39). It is also of interest that the
391 mutant, lacking ability to generate STAT5a/b, did not show
sexual dimorphism in growth, as was also observed in the
STAT5b/ mice (35). This correlates with an inability to
express the male-specific MUP transcripts and protein in the
391 line, as well as feminization of its cytochrome P450 profile
in the liver.
Our in vivo finding that ERK activation is normal with the
391 truncation is in contrast to the findings of some in vitro
studies (38) but not others (3, 33). A second in vitro conclusion
that was not verified in vivo is the lack of involvement of
tyrosine m498 and proximal tyrosine in the generation of ac-
tivated STAT5 (8). In support of this, other in vitro studies (32)
have proposed that tyrosines m498 and m545 are responsible
for most of the STAT5 activation. As is evident here, tyrosines
m401, m447, and m498 (most likely tyrosine m498 [30]) can
generate ca. 30% of active STAT5 in the liver. The lack of
ability of the 391 truncated mutant to generate STAT5 elimi-
nates a role for tyrosines m333 and m338 in generating active
hepatic STAT5.
The present study has used the novel approach of combining
transcript analysis by microarray with the creation of mice
bearing targeted mutations within the cytoplasmic sequence of
the GH receptor in order to define the role of signaling do-
mains within the receptor. We have been able to define a
limited set of 35 hepatic transcripts (5 exclusively) which are
regulated by the carboxy-terminal 80 residues, and the two
adjacent tyrosines (Fig. 6A). This domain generates the ma-
jority of active STAT5, and this is likely to be the instrumental
agent in regulating these mainly metabolic genes. Accordingly,
some of the P450 cytochromes that are known STAT5a targets,
as shown by their increase in the STAT5a/ mice, had their
expression increased by deletion of this region (22). Microar-
TABLE 3. Simplified gene ontology classification of genes
differentially expressed in three transgenic lines
in comparison to the WT
Type or function
No. of genes
Mutant
569
Mutant
391
GHR/
control
Metabolism 12 26 60
Cytochrome/electron transport 5 12 22
Glutathione/antioxidant 2 8 10
Transporters 1 16 20
Proliferation/differentiation/growth 2 10 30
Cell-to-cell interactions 0 1 5
Transcription/translation 0 0 23
Signaling 1 13 28
Protein processing 4 18 17
Chaperones 1 1 7
Ribosomal proteins 0 1 17
Unclassified 6 15 91
Total 35 121 330
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ray analysis of STAT5a/b/ double-mutant mice should allow
further definition of these regulated genes.
Despite the major involvement of residues m391 to m650 in
regulating growth, the loss of the remaining receptor signaling
results in a substantially greater number of altered transcripts
(n  330, compared to 121 for the mutant 391). The majority
of transcripts changed in mutant 391 are downregulated in
contrast to GHR/ mice (Fig. 6A). This observation can be
explained by the presence of binding sites in this truncated
mutant, for negative regulators such as SOCS proteins,
whereas all repression normally provided by GH signaling is
lost in GHR/ mice. In addition, these changes are accom-
panied in GHR/ mice by upregulation of a number of im-
portant transcription factors (e.g., Nr4a, Bcl6, Dbp, and Egr-1),
as well as translational regulators.
The present study has provided substantial new data on the
physiological roles of GH in hepatic function, since large-scale
microarrays have not previously been applied to GHR gene-
disrupted mice. Indeed, the only microarray study using Clon-
tech Atlas gene arrays (with 1,176 genes) on the GHR/ mice
identified only 10 regulated transcripts (17), with 6 of them
confirmed in the present study. Several patterns emerging from
the transcriptome analysis are clearest in the GHR/ mice.
Transcripts related to protein synthesis and RNA metabolism
are increased, whereas a number of transcripts encoding the
serine protease inhibitor family were decreased. This could
potentially decrease protein turnover and activation and lead
to abnormal accumulation and/or actions of proteases. The
changes observed in transcripts encoding metabolic enzymes,
for example, in lipid and cholesterol metabolism (Scd1, Decr1,
Ech1, and Acaa1) confirm a previous study showing GH reg-
ulation (36). Changes in genes involved in cholesterol metab-
olism involved not only genes necessary for its synthesis and
cellular uptake but also for cholesterol conversion to bile acids
(Csad). The latter was highly decreased, which can be expected
to elevate the hepatic cholesterol levels. The changes in cho-
lesterol availability would also affect steroid metabolism, and
there were changes in transcripts encoding genes regulating
this pathway. Transcript for one of the enzymes (Hsd3b5) was
reduced in all mutants; however, in mutant 391 five other genes
of this family were decreased. A number of transcripts encod-
ing sugar-metabolizing enzymes (e.g., G6pc and Pfkfb1) were
increased in the GHR/ mice, with mild changes in mutant
391 and no changes in mutant 569. One of the important
changes observed was an increase in transcripts encoding pro-
teins of the beta-oxidation (Acadl, Hao3, and 1300002P22
Rik), electron transport chain (family of NADH dehydroge-
nases and cytochrome oxidases), and trichloroacetic acid cycle
(Idh3g and Suclg1) would indicate higher energy production in
GHR/ mice. At least some of these changes would account
for many of the phenotypes observed in GH-deficient patients
and animals. However, the finding of obesity in both lines in
later life does not correlate with the observed changes in he-
patic lipid metabolism. The answer in this case is likely to be in
the adipose tissue itself. GH-deficient lit/lit mice exhibit obesity
in maturity, as did the older mutant mice in the present study.
A likely cause of this is the deficiency of STAT5a, which is
required for GH-dependent lipolysis in adipose tissue (6).
There may also be a contribution to lipogenesis from the con-
tinuing drive to the distal receptor domain from elevated GH
levels in plasma resulting from the lowered levels of IGF-1 in
plasma.
An interesting finding in the young adult mice was the iden-
tification of a number of transcripts known to be important in
regulating insulin sensitivity. These include the fatty acid-bind-
ing proteins 2 and 5, lipin 2, insulin-degrading enzyme, corti-
sol-binding globulin (Serpina6), and the induced in fatty liver
dystrophy 2 transcript (Ifld2). Increased insulin sensitivity and
decreased IGF-1 and insulin levels found in long- lived
GHR/ mice are concordant with these findings (4), although
the elevated blood glucose in older animals (associated with
obesity) would argue against this in the long term. Interest-
ingly, 14 transcripts associated with life span extension in Cae-
norhabditis elegans are similarly regulated in the GHR/
mice, raising the possibility that the life extension is not related
to insulin. It will be important to determine whether mutant
569 with lowered IGF1 and mild growth retardation displays
longevity similar to the heterozygous IGF1R/ mouse (11),
or if this is only seen with extreme suppression of IGF-1, as
seen in the mutant 391, or correlates with loss of GH stimu-
lated PI 3-kinase and ERK1/2 activity, as seen in the GHR/
mice.
The present study has described the role of the various parts
of the cytoplasmic domain of GHR in generating growth sig-
nal, indicated significant changes in metabolism associated
with mutations of GHR (Fig. 6E), and provided evidence for
novel roles of GH. In particular, the changes observed in
GHR/ mice indicated a role of GH in regulating mRNAs for
transcription factors critical in promoting inflammation
(Ppar, Nr4a1, and Bcl6) and transcripts for complement
genes, for Rgs16 and Zap 70, and for interleukin-1 receptor
antagonist, which together could account for the mortality
observed when GH treatment is given to critically ill patients.
In many cases the known roles of GH are more extensive than
previously thought as, for example, in the regulation of anti-
oxidant and glutathione metabolism, serum proteins, Serpin
genes, RNA/DNA-binding proteins, chaperones, and ribo-
somal proteins, the latter presumably increasing translation
efficiency. The results presented here also show that the GH-
regulated metabolic functions can be successfully studied in
our GHR mutant animals. Such studies will, however, require
a physiological stress (e.g., induction of diabetes or use of
specific diet) to determine how various enzymes and other
proteins are regulated by remaining GH signaling. Further
defining of the in vivo signaling pathways responsible for the
regulation of expression of GH-induced genes will be facili-
tated by other targeted mutations to the cytoplasmic domain of
the GH receptor.
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